Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Modified Radical Mastectomy

Modified Radical Mastectomy

Modified radical mastectomy is a surgical procedure for breast cancer treatment that involves the removal of the entire breast, nipple, and some of the underarm lymph nodes.
This procedure aims to reduce the risk of cancer recurrence while preserving more of the breast tissue compared to a traditional radical mastectomy.
The modified approach may offer improved cosmetic outcomes and physical function for patients.
Researchers can use PubCompare.ai's AI-driven platform to streamline the identification and comparison of modified radical mastectormy protocols across literature, preprints, and patents, enhacning research reproducibility and identifying optimal procedures and products.

Most cited protocols related to «Modified Radical Mastectomy»

1
Breast Cancer Tissue Sampling Study
Cited 26 times
Fresh frozen breast cancer tissue from every third patient diagnosed and treated between 1991 and 2004 at the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) were randomly selected for the study. Patients with follow-up periods shorter than three years were excluded, with the exception of those who died of the disease within three years of the initial treatment. In cases of ineligibility, the following sample was selected. The selected tissue samples spanned the major transition periods of adjuvant chemotherapy from CMF (cyclophosphamide, methotrexate and fluorouracil) to CAF (cyclophosphamide, doxorubicin, fluorouracil) and to taxane-based regimens. Four hundred forty seven samples were obtained, but 135 samples were excluded due to insufficient RNA (n = 1), poor RNA quality (n = 116), or unacceptable microarray quality (n = 18). A total of 312 samples were eligible for the study (Cohort 1). Gene expression profiles of an additional 15 lobular breast carcinoma samples, collected between 1999 and 2004 and previously studied, were also included (Cohort 2). All patients were treated by a multidisciplinary team according to the guidelines consistent with the National Comprehensive Cancer Network [18 ]. Following modified radical mastectomy or breast-conserving surgery plus dissection of axillary nodes, patients received radiotherapy, adjuvant chemotherapy, and/or hormonal therapy, if indicated. Neoadjuvant chemotherapy was administered to patients with locally advanced disease. The study was approved by the institutional review board (ID number 20020128A) and ethical approval was obtained from the same board for samples without obtainable informed consent.
Kao K.J., Chang K.M., Hsu H.C, & Huang A.T. (2011). Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer, 11, 143.
Full text: Click here
Publication 2011
Axilla Breast-Conserving Surgery Carcinoma, Lobular Chemotherapy, Adjuvant Cyclophosphamide Dissection Doxorubicin Ethics Committees, Research Fluorouracil Freezing Malignant Neoplasm of Breast Malignant Neoplasms Methotrexate Microarray Analysis Modified Radical Mastectomy Neoadjuvant Chemotherapy Patients Radiotherapy taxane Therapeutics Tissues Treatment Protocols
2
Surgical Removal of Mammary Tumors
Cited 5 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Autopsy Breast Buprenorphine Capsule Clip Groin Hemostasis Isoflurane Modified Radical Mastectomy Mus Neoplasms Nodes, Lymph Operative Surgical Procedures Skin Survivors Tissues Wounds
3
Identifying Mastectomies in Claims Data
Cited 5 times
We identified mastectomy operations with at least one day follow-up after operation among women aged 18–64 years from 1/1/2004–12/31/2011 using ICD-9-CM and/or CPT-4 procedure codes from inpatient and outpatient facility and provider claims (Appendix 1). Because of coding inaccuracy and the limited clinical detail in claims data, we implemented steps to increase the likelihood that the procedures we included were truly mastectomies, as described below. We allowed a maximum of two mastectomies per woman during the study period. We excluded claims that contained CPT-4, HCPCS, or UB-04 revenue codes truncated to 4 digits and populated in the fields reserved for ICD-9-CM procedure codes and claims in which a mastectomy procedure code was present only on one line on a single claim with no other claims on the same date, as described previously.8 In 1,300 (6.7%) operations, CPT-4 or ICD-9-CM procedures codes for BCS were present during the same hospital admission or within 3 days of mastectomy. Since concurrent BCS and mastectomy is unlikely and the incidence of SSI after BCS is lower than after mastectomy, we created an algorithm to determine the most likely procedure. We included any of the following information as evidence that mastectomy was performed: procedure code for reconstruction (Appendix 1), CPT-4 pathology code 88309 (modified radical mastectomy), prophylactic removal of the breast (V50.41), mastectomy coded by both facility and surgeon, BCS and mastectomy on opposite breasts per CPT-4 modifier codes, BCS coded only by an assistant surgeon, or diagnosis of acquired absence of the breast in the year following surgery (V45.71). We excluded procedures more consistent with BCS, including surgeon coding only for BCS (mastectomy-only coded by assistant surgeon or facility), and other diagnoses and procedures consistent with BCS but not mastectomy (Appendix 2).9
Olsen M.A., Nickel K.B., Fox I.K., Margenthaler J.A., Ball K.E., Mines D., Wallace A.E, & Fraser V.J. (2015). Incidence of Surgical Site Infection Following Mastectomy With and Without Immediate Reconstruction Using Private Insurer Claims Data. Infection control and hospital epidemiology, 36(8), 907-914.
Publication 2015
Breast Condoms Diagnosis Fingers Inpatient Mastectomy Modified Radical Mastectomy Operative Surgical Procedures Outpatients Reconstructive Surgical Procedures Surgeons Surgery, Day Woman
4
Adjuvant Chemotherapy for Node-Positive Breast Cancer
Cited 5 times
Patients meeting the following characteristics were chosen from electronically archived medical records: (1) Curative resection of breast cancer at Seoul National University Hospital, Korea between 1999 and 2004; (2) Pathologically determined involvement of 4 or more lymph nodes; (3) The administration of AC/T as an adjuvant chemotherapy; (4) No trastuzumab adjuvant therapy; and (5) Sufficient tissue samples available for immunohistochemical analysis.
Adjuvant chemotherapy consisted of 60 mg/m2 doxorubicin and 600 mg/m2 cyclophosphamide every 3 weeks for 4 cycles followed by 175 mg/m2 paclitaxel every 3 weeks for 4 cycles [3 (link)]. Adjuvant radiotherapy or hormonal therapy was performed as appropriate.
One hundred and fifty one patients, including 3 male patients, met these inclusion criteria and were included in this study. Patients with stage IIIB disease (T4 by AJCC staging) were not included in this study, because these patients were treated with a neoadjuvant chemotherapy protocol. Thus, all 151 patients were at stage IIIA or IIIC disease. Surgical treatment was radical modified mastectomy, without removal of the pectoralis muscles, in 120 cases (79.5%) and breast conserving surgery including quadrantectomy in 31 cases (20.5%). A level II axillary dissection was performed in all patients and the mean number of lymph nodes removed was 22.9 (range 7–54). Of the 151 patients, 89 (58.9%) were ER and/or PR positive, and 87 (97.8%) of these patients received 5 years of adjuvant tamoxifen. Thirty-one patients received breast-conserving surgery and all, except one lost to follow-up, received adjuvant radiotherapy. Of the 120 patients who underwent modified radical mastectomy, 108 received adjuvant radiotherapy. Patient characteristics are listed in Table 1.
Lee K.H., Im S.A., Oh D.Y., Lee S.H., Chie E.K., Han W., Kim D.W., Kim T.Y., Park I.A., Noh D.Y., Heo D.S., Ha S.W, & Bang Y.J. (2007). Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer, 7, 63.
Full text: Click here
Publication 2007
Axilla Breast-Conserving Surgery Chemotherapy, Adjuvant Cyclophosphamide Dissection Doxorubicin Males Malignant Neoplasm of Breast Mastectomy, Radical Modified Radical Mastectomy Neoadjuvant Chemotherapy Nodes, Lymph Operative Surgical Procedures Paclitaxel Patients Pectoralis Muscles Pharmaceutical Adjuvants Radiotherapy, Adjuvant Tamoxifen Therapeutics Tissues Trastuzumab
5
Survival of Breast Cancer Subtypes
Cited 3 times
In a clinical study, survival of mixed lobular and ductal carcinomas of breast cancer was compared with a series of patients with pure invasive ductal ones. One hundred and thirty-two patients, ninety-eight with ductal carcinomas and thirty-four with mixed who had been treated by modified radical mastectomy, were followed for 10 years [26 (link)]. Survival data were available for all patients with a minimum of five-year follow-up period. At the end of follow-up time, their survivorship was assessed in relation to the histological type of tumor. The data are presented in Table 2.
The OR and RR of five-year mortality for the mixed versus ductal type were, respectively: OR=a⋅db⋅c=26⋅608⋅38=5.13, 
RR=ac+dca+b=26⋅9838⋅34=1.97
Moreover, the 95% Confidence Intervals (CIs) of OR and RR were: 95% CΙ OR (2.11, 12.50) and 95% CI RR (1.45, 2.69).
Gnardellis C., Notara V., Papadakaki M., Gialamas V, & Chliaoutakis J. (2022). Overestimation of Relative Risk and Prevalence Ratio: Misuse of Logistic Modeling. Diagnostics, 12(11), 2851.
Full text: Click here
Publication 2022
Breast Carcinoma Ductal Carcinoma Modified Radical Mastectomy Neoplasms by Histologic Type Patients

Most recents protocols related to «Modified Radical Mastectomy»

1
Estradiol Levels in Breast Cancer Patients Pre- and Post-Chemotherapy
This was quantitative research in the form of prospective cohort observations at Dr. Moewardi Hospital between April 2021 and May 2022. This study observed changes in estradiol levels before and after adjuvant chemotherapy in breast cancer patients. The inclusion criteria were breast cancer patients who had undergone modified radical mastectomy or simple mastectomy, planned to undergo six cycles of chemotherapy, and had never received hormonal therapy or neoadjuvant chemotherapy. The exclusion criteria were comorbidities or conditions that could increase estradiol levels; patients lost to follow-up, namely, chemotherapy was not on schedule; incomplete chemotherapy; and death during chemotherapy.
Primary data collection included age, sex, and risk factors for breast cancer. Data on cancer included cancer stage, cell type, grade, subtype, and chemotherapy regimen. The estradiol levels were taken in the morning regarding the patient’s menopausal status, with normal values of 90 - 270 pg/mL using the DRG Estradiol ELISA, an immunoassay enzyme used for measuring the in vitro diagnostic quantity of estradiol in serum and plasma [6 ]. The estradiol levels were taken twice. The first was before the patient underwent the first cycle, and the second was 3 weeks after the patient went through the sixth cycle of chemotherapy.
Soewoto W, & Agustriani N. (2023). Estradiol Levels and Chemotherapy in Breast Cancer Patients: A Prospective Clinical Study. World Journal of Oncology, 14(1), 60-66.
Publication 2023
Breast Cells Chemotherapy, Adjuvant Diagnosis Enzyme-Linked Immunosorbent Assay Enzymes Estradiol Immunoassay Malignant Neoplasm of Breast Malignant Neoplasms Menopause Modified Radical Mastectomy Neoadjuvant Chemotherapy Patients Pharmacotherapy Plasma Serum Simple Mastectomy Staging, Cancer Therapeutics Treatment Protocols
2
Chemotherapy and Immunotherapy in TNBC
The chemotherapy trial was from the southwest hospital containing 15 TNBC patients with TE regimen (paclitaxel/docetaxel, epirubicin) or TEC regimen (docetaxel, epirubicin and cyclophosphamide) for neoadjuvant chemotherapy. The biopsies were taken at their first to doctor as pre-chemotherapy samples and the intraoperative specimens were taken after the neoadjuvant treatment as post-chemotherapy samples. The immunotherapy cohort was from the FUTURE trial C arm (NCT03805399). These patients were with locally advanced or metastatic TNBC progressed after standard chemotherapy including taxol. Intraoperative specimens were taken in the radical mastectomy or modified mastectomy as pre-chemotherapy samples. With standard chemotherapy failure, the progressive and unresectable tumor biopsies were taken as post-chemotherapy samples before being treated with nab-paclitaxel plus anti-PD-1 antibodies, which were regarded as the baseline of chemoimmunotherapy. For the survival analysis, we collected 399 breast cancer patients for the multicentric clinical cohort from Chongqing (147 cases), Guangzhou (89 cases) and Beijing (163 cases) trials. Most patients have undergone radical mastectomy or modified mastectomy and have received the standard chemotherapy. All procedures were approved by the Ethics Committee of the First Affiliated Hospital of Army Medical University (KY20200305). Informed consent was obtained from all patients.
Xie X.Q., Yang Y., Wang Q., Liu H.F., Fang X.Y., Li C.L., Jiang Y.Z., Wang S., Zhao H.Y., Miao J.Y., Ding S.S., Liu X.D., Yao X.H., Yang W.T., Jiang J., Shao Z.M., Jin G, & Bian X.W. (2023). Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell Research, 33(3), 215-228.
Full text: Click here
Publication 2023
130-nm albumin-bound paclitaxel Anti-Antibodies Biopsy Cyclophosphamide Docetaxel Epirubicin Ethics Committees, Clinical Immunotherapy Malignant Neoplasm of Breast Mastectomy, Radical Modified Radical Mastectomy Neoadjuvant Chemotherapy Neoadjuvant Therapy Neoplasms Paclitaxel Patients Pharmacotherapy Physicians Taxol TEC regimen Treatment Protocols
3
HER2-Positive Breast Cancer Treatement Outcomes

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Axilla Biologic Preservation Breast Breast-Conserving Surgery Breast Carcinoma Breast Neoplasm Carboplatin Core Needle Biopsy ERBB2 protein, human Ethics Committees, Clinical Fluorescent in Situ Hybridization Immunohistochemistry Inflammatory Breast Carcinoma Lymph Node Excision Lymph Node Metastasis Mastectomy Menopause Modified Radical Mastectomy Neoplasm Metastasis Nodes, Lymph Operative Surgical Procedures Patients Pharmaceutical Adjuvants Pharmacotherapy Radiotherapy Recurrence Sentinel Lymph Node Biopsy taxane Therapeutics Thoracic Surgical Procedures Trastuzumab Vessel, Lymphatic
4
Clinicopathological Features and Survival Analysis of Breast Cancer Subgroups
Descriptive statistics of the clinicopathologic features of the 473 tumors were calculated. All cases of Group 2 were grouped for different cutoffs of average HER2 signals, average CEP17 signals, and HER2/CEP17 ratio, respectively. Various tumor characteristics were compared between these groups using the Pearson chi-square test aiming at evaluating the relationship between different groups. A total of 57 patients of Group 2 who were primary breast cancer without neoadjuvant therapy and underwent modified radical mastectomy were selected and matched with 374 patients of Group 5 for further comparison analysis of clinicalpathological characteristics. The Fisher exact tests were performed when necessary. All statistical tests were two-sided, and P values less than 0.05 were considered as significant. Disease free survival (DFS) was the primary end point, defined as local or regional recurrence, distant metastasis, or death from any cause. DFS and overall survival (OS) of Group 2 were estimated using the Kaplan-Meier method. All analyses were performed in SPSS (version 17.0, SPSS Company, Chicago, IL).
Zhou S., Lv H., Li A., Li M., Zhong S., Lu H., Zhou X., Bai Q, & Yang W. (2023). A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China. BMC Cancer, 23, 84.
Full text: Click here
Publication 2023
ERBB2 protein, human Malignant Neoplasm of Breast Modified Radical Mastectomy Neoadjuvant Therapy Neoplasm Metastasis Neoplasms Patients Recurrence
5
Elective Mastectomy for Breast Cancer

ASA grade I-II

35-55years, 45-70 kg

Underwent elective modified radical mastectomy for breast cancer

Complete clinical data

Fei G., Yan W, & Yao H. (2023). Effect of single intravenous injection of esketamine on quality of recovery during early period after modified radical mastectomy for breast cancer: A retrospective study. Pakistan Journal of Medical Sciences, 39(6), 1763-1767.
Full text: Click here
Publication 2023
Malignant Neoplasm of Breast Modified Radical Mastectomy

Top products related to «Modified Radical Mastectomy»

1
Spss 25.0 program by IBM
Sourced in United States
SPSS 25.0 is a statistical software program developed by IBM. It is designed to perform data analysis, information management, and predictive analytics. The program provides a wide range of tools for data manipulation, analysis, and visualization. SPSS 25.0 is commonly used in various industries, including research, academia, and business, for tasks such as survey data analysis, forecasting, and decision-making.
2
Mda mb 231 by National Collection of Authenticated Cell Cultures
Sourced in China, United States
The MDA-MB-231 is a cell line derived from a human breast adenocarcinoma. It is a commonly used model for breast cancer research.
3
Rnalater solution by Thermo Fisher Scientific
Sourced in United States, Germany, Lithuania, United Kingdom, Canada, France, Japan, Israel, Australia, Spain, Switzerland, Sweden
RNAlater solution is a nucleic acid stabilization reagent that immediately stabilizes and protects RNA in fresh tissue samples. It preserves the RNA in tissues and cells, preventing degradation and allowing for reliable downstream analysis.
4
Stata statistical software package by StataCorp
Sourced in United States
Stata is a comprehensive, integrated statistical software package. It provides a wide range of data management, statistical analysis, and graphical tools for researchers and analysts. Stata is designed to handle a variety of data types and supports a diverse range of statistical techniques, including regression analysis, time series analysis, and multilevel modeling.
5
Dneasy tissue kit by Qiagen
Sourced in Germany, United States, Spain, France, Canada, China, United Kingdom, Japan, Switzerland, Netherlands, Italy
The DNeasy Tissue Kit is a DNA extraction and purification system designed for the isolation of genomic DNA from a variety of sample types, including animal tissues, plant materials, and microorganisms. The kit utilizes a spin-column-based procedure to efficiently capture and purify DNA, which can then be used in downstream applications such as PCR, sequencing, and other molecular biology techniques.
6
Spss v17 by IBM
Sourced in United States, Belgium, United Kingdom
SPSS v17.0 is a software application developed by IBM for the purpose of statistical analysis. It provides a range of tools and functionalities for data management, analysis, and reporting. The software is designed to assist users in organizing, analyzing, and interpreting data from various sources.
7
Foetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, United Kingdom, China, Australia, Germany, France, Italy, Japan, Switzerland, Spain, New Zealand, Ireland, Belgium, Canada, Austria, Brazil, Israel, Portugal, Denmark, Sweden
Foetal bovine serum is a cell culture supplement derived from the blood of bovine fetuses. It provides a complex mixture of growth factors, hormones, and other nutrients essential for the in vitro growth and proliferation of a wide range of cell types.
8
Mcf 10a by Lonza
Sourced in United States, Switzerland, Canada
The MCF-10A is a human breast epithelial cell line that is widely used in cell biology research. It is a non-tumorigenic cell line that can be used to study normal breast epithelial cell function. The MCF-10A cells are a valuable tool for researchers investigating various aspects of breast biology, including cell signaling, differentiation, and tissue architecture.
9
Rnalater solution by Merck Group
Sourced in United States, Germany, United Kingdom, Poland
RNAlater solution is a RNA stabilization reagent designed to protect and preserve RNA molecules in biological samples. It inhibits RNA degradation and maintains the integrity of RNA for subsequent analysis or storage.
10
Spss 16 by IBM
Sourced in United States, United Kingdom, India, China, Belgium, Denmark
SPSS 16.0 is a software package for statistical analysis. It provides tools for data management, analysis, and presentation. The core function of SPSS 16.0 is to enable users to perform a variety of statistical procedures, including descriptive statistics, regression analysis, and hypothesis testing.

More about "Modified Radical Mastectomy"

Modified Radical Mastectomy (MRM) is a surgical procedure used to treat breast cancer.
It involves the removal of the entire breast, nipple, and some of the underarm lymph nodes.
This approach is a modification of the traditional radical mastectomy, aiming to reduce the risk of cancer recurrence while preserving more of the breast tissue.
The modified technique may offer improved cosmetic outcomes and physical function for patients compared to the traditional method.
Researchers can leverage PubCompare.ai's AI-driven platform to streamline the identification and comparison of MRM protocols across literature, preprints, and patents.
This can enhance research reproducibility and help identify the optimal procedures and products for MRM.
By utilizing the power of AI, researchers can improve their research process and outcomes.
In addition to MRM, other related terms and concepts that may be relevant include SPSS 25.0 (a statistical software package), MDA-MB-231 (a breast cancer cell line), RNAlater solution (a reagent used for RNA preservation), Stata statistical software package, DNeasy Tissue Kit (a DNA extraction kit), SPSS v17.0, Foetal bovine serum (a common cell culture supplement), MCF-10A (a non-cancerous breast epithelial cell line), and SPSS 16.0.
These tools and techniques can be utilized in various aspects of breast cancer research, including the study and refinement of MRM procedures.
By incorporating these related terms and concepts, researchers can enhance their understanding and exploration of the field of Modified Radical Mastectomy, leading to improved treatments and outcomes for breast cancer patients.